⚡ Shingles (Zoster) Vaccines
3 major studies graded on 9 RCT methodology criteria.
Shingles vaccines have some of the strongest trial evidence in the adult vaccine space. The original Zostavax trial enrolled over 38,000 veterans in a landmark government-funded study with multi-year follow-up. Its successor Shingrix showed dramatically higher efficacy (97% vs ~51%) and was tested in similarly large, rigorous Phase 3 trials.
🧪 What do these 9 criteria mean? click to expand
A comparison group received a different treatment (or no treatment) under identical conditions.
Without a control group, you cannot determine whether changes in outcomes were caused by the vaccine or other factors.
Participants were randomly assigned to vaccine or control — not by age, risk, or researcher choice.
Randomization prevents selection bias, ensuring the vaccinated and unvaccinated groups are comparable at baseline.
Neither participants nor researchers measuring outcomes knew who received the vaccine.
Blinding prevents both reporting bias (participants feeling better just from getting a shot) and measurement bias.
The control group received an inert substance (saline) — not another active vaccine.
Active comparators can mask safety signals. If the control group also experiences side effects, adverse events in the test group may appear deceptively normal.
At least 1,000 participants were enrolled.
Larger samples detect modest effects and rare adverse events. A 200-person study might miss a side effect affecting 1 in 500.
Participants were tracked for at least one year after vaccination.
Short follow-up windows miss delayed adverse events, waning immunity, and long-term effectiveness.
Funded primarily by government, universities, or non-profits — not the manufacturer.
Industry-funded trials are statistically more likely to show positive results for the funder's product. This is a documented pattern, not an accusation.
Published in a peer-reviewed journal after independent scientific review.
Peer review catches methodological errors, though it is not a guarantee of correctness.
Independent researchers or real-world surveillance data confirmed the core findings.
Single trials can contain errors. When multiple independent studies find similar results, confidence increases substantially.
Study Summary
The landmark shingles vaccine trial — one of the largest and most rigorous adult vaccine studies ever. Enrolled 38,546 adults aged 60+ at 22 US sites. Found Zostavax reduced shingles by 51.3% and postherpetic neuralgia (PHN) by 66.5% over ~3 years. Government-led with Merck as secondary funder.
Strengths
Exceptional sample size (38,546). Three-year median follow-up — rare in vaccine trials. Government-led with independent oversight. Saline placebo. Confirmed by two decades of real-world data.
Limitations
Merck co-funded (though government agencies led). Efficacy waned below 50% by year 6–7 in long-term follow-up. Zostavax has since been replaced by Shingrix, which showed 97% efficacy.
Study Summary
Phase 3 trial of Shingrix in 15,411 adults aged 50+. Reported 97.2% efficacy against shingles at median 3.2-year follow-up. Companion ZOSTER-022 trial confirmed findings in adults 70+. Shingrix has replaced Zostavax as the preferred shingles vaccine.
Strengths
97% efficacy, large, 3+ year follow-up. Double-blind, saline placebo-controlled. Confirmed by companion ZOSTER-022, ZOSTER-028 trials and extensive real-world post-marketing data.
Limitations
Entirely GSK-funded. Reactogenicity (arm soreness, fever, fatigue after dose 2) is higher than most vaccines — notable in older adults. Long-term immunity beyond 10 years still under study.
Study Summary
Phase 3 trial of Shingrix in 1,846 adults post-stem cell transplant — a high-risk population excluded from original Shingrix trials. Reported 68.2% efficacy against shingles over 21 months. Established Shingrix as safe and effective in immunocompromised adults.
Strengths
Addressed an important high-risk population. Randomized, double-blind, placebo-controlled. Published in NEJM.
Limitations
Smaller sample (1,846). 21-month follow-up only. Entirely GSK-funded. Efficacy (68%) substantially lower than in immunocompetent adults (97%), which is expected but worth noting.
📋 What This Means
Shingles vaccines — particularly Shingrix — have the most robust RCT evidence of any vaccine on this site. The original Zostavax trial was government-co-funded with long follow-up, a methodological gold standard. Shingrix trials were manufacturer-funded but otherwise exemplary: large, blinded, placebo-controlled, with multi-year data. Independent studies have confirmed >85% real-world protection with Shingrix.